Innoviva Pre-Tax Profit Margin 2011-2025 | INVA
Innoviva pre-tax profit margin from 2011 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Innoviva Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-06-30 | $0.37B | $0.07B | 17.79% |
| 2025-03-31 | $0.37B | $-0.05B | -12.40% |
| 2024-12-31 | $0.36B | $0.04B | 10.58% |
| 2024-09-30 | $0.35B | $0.07B | 20.96% |
| 2024-06-30 | $0.33B | $0.15B | 46.36% |
| 2024-03-31 | $0.31B | $0.20B | 63.67% |
| 2023-12-31 | $0.31B | $0.19B | 62.58% |
| 2023-09-30 | $0.29B | $0.07B | 23.45% |
| 2023-06-30 | $0.29B | $0.27B | 92.41% |
| 2023-03-31 | $0.32B | $0.28B | 88.96% |
| 2022-12-31 | $0.33B | $0.29B | 86.40% |
| 2022-09-30 | $0.37B | $0.41B | 109.12% |
| 2022-06-30 | $0.40B | $0.24B | 60.40% |
| 2022-03-31 | $0.40B | $0.36B | 90.68% |
| 2021-12-31 | $0.39B | $0.44B | 112.98% |
| 2021-09-30 | $0.38B | $0.48B | 127.73% |
| 2021-06-30 | $0.37B | $0.41B | 110.93% |
| 2021-03-31 | $0.34B | $0.39B | 112.79% |
| 2020-12-31 | $0.34B | $0.35B | 105.04% |
| 2020-09-30 | $0.32B | $0.33B | 103.10% |
| 2020-06-30 | $0.30B | $0.34B | 113.67% |
| 2020-03-31 | $0.29B | $0.28B | 97.89% |
| 2019-12-31 | $0.26B | $0.23B | 89.27% |
| 2019-09-30 | $0.27B | $0.24B | 89.06% |
| 2019-06-30 | $0.26B | $0.23B | 87.36% |
| 2019-03-31 | $0.26B | $0.23B | 86.74% |
| 2018-12-31 | $0.26B | $0.21B | 80.46% |
| 2018-09-30 | $0.25B | $0.20B | 78.09% |
| 2018-06-30 | $0.24B | $0.17B | 71.43% |
| 2018-03-31 | $0.23B | $0.15B | 64.35% |
| 2017-12-31 | $0.22B | $0.14B | 61.93% |
| 2017-09-30 | $0.19B | $0.10B | 53.13% |
| 2017-06-30 | $0.18B | $0.09B | 52.84% |
| 2017-03-31 | $0.15B | $0.07B | 48.99% |
| 2016-12-31 | $0.13B | $0.06B | 45.11% |
| 2016-09-30 | $0.11B | $0.04B | 33.93% |
| 2016-06-30 | $0.09B | $0.02B | 19.35% |
| 2016-03-31 | $0.07B | $-0.01B | -6.94% |
| 2015-12-31 | $0.06B | $-0.02B | -36.36% |
| 2015-09-30 | $0.04B | $-0.04B | -102.56% |
| 2015-06-30 | $0.03B | $-0.06B | -219.23% |
| 2015-03-31 | $0.02B | $-0.07B | -431.25% |
| 2014-12-31 | $0.01B | $-0.07B | -925.00% |
| 2014-09-30 | $0.00B | $-0.04B | -2000.00% |
| 2014-06-30 | $0.00B | $-0.03B | -2700.00% |
| 2014-03-31 | $0.00B | $-0.01B | -900.00% |
| 2013-12-31 | $0.00B | $-0.03B | -1000.00% |
| 2013-09-30 | $0.01B | $-0.08B | -987.50% |
| 2013-06-30 | $0.01B | $-0.11B | -1166.67% |
| 2013-03-31 | $0.01B | $-0.14B | -1555.56% |
| 2012-12-31 | $0.14B | $-0.02B | -13.33% |
| 2012-09-30 | $0.13B | $-0.02B | -17.91% |
| 2012-06-30 | $0.14B | $-0.02B | -14.39% |
| 2012-03-31 | $0.14B | $-0.01B | -5.56% |
| 2011-12-31 | $0.02B | $-0.12B | -504.35% |
| 2011-09-30 | $0.03B | $-0.10B | -392.00% |
| 2011-06-30 | $0.02B | $-0.09B | -366.67% |
| 2011-03-31 | $0.02B | $-0.08B | -350.00% |
| 2010-12-31 | $0.02B | $-0.08B | -350.00% |
| 2010-09-30 | $0.02B | $-0.09B | -414.29% |
| 2010-06-30 | $0.02B | $-0.09B | -400.00% |
| 2010-03-31 | $0.02B | $-0.09B | -423.81% |
| 2009-12-31 | $0.03B | $-0.09B | -340.00% |
| 2009-09-30 | $0.03B | $-0.08B | -292.59% |
| 2009-06-30 | $0.03B | $-0.08B | -288.89% |
| 2009-03-31 | $0.03B | $-0.08B | -296.43% |
| 2008-12-31 | $0.02B | $-0.09B | -391.67% |
| 2008-09-30 | $0.02B | $-0.11B | -462.50% |
| 2008-06-30 | $0.02B | $-0.12B | -508.33% |
| 2008-03-31 | $0.02B | $-0.14B | -608.70% |
| 2007-12-31 | $0.02B | $-0.16B | -722.73% |
| 2007-09-30 | $0.02B | $-0.16B | -780.95% |
| 2007-06-30 | $0.02B | $-0.17B | -809.52% |
| 2007-03-31 | $0.02B | $-0.17B | -790.48% |
| 2006-12-31 | $0.02B | $-0.17B | -830.00% |
| 2006-09-30 | $0.02B | $-0.17B | -944.44% |
| 2006-06-30 | $0.02B | $-0.17B | -1133.33% |
| 2006-03-31 | $0.01B | $-0.16B | -1238.46% |
| 2005-12-31 | $0.01B | $-0.14B | -1191.67% |
| 2005-09-30 | $0.01B | $-0.13B | -1083.33% |
| 2005-06-30 | $0.01B | $-0.11B | -950.00% |
| 2005-03-31 | $0.01B | $-0.11B | -1018.18% |
| 2004-12-31 | $0.01B | $-0.10B | -1133.33% |
| 2004-09-30 | $0.01B | $-0.09B | -1285.71% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.404B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $962.193B | 46.28 |
| Johnson & Johnson (JNJ) | United States | $468.343B | 18.73 |
| AbbVie (ABBV) | United States | $412.207B | 24.68 |
| Roche Holding AG (RHHBY) | Switzerland | $289.080B | 0.00 |
| Novartis AG (NVS) | Switzerland | $279.452B | 14.81 |
| Merck (MRK) | United States | $226.981B | 10.57 |
| Novo Nordisk (NVO) | Denmark | $224.411B | 13.16 |
| Pfizer (PFE) | United States | $147.089B | 8.08 |
| Sanofi (SNY) | France | $127.490B | 12.24 |
| Bayer (BAYRY) | Germany | $32.892B | 5.77 |